Clinical trial · no report yet · Phase 3
STAMPEDE 2
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
- NCT06320067 ↗
- Recruiting
- University College, London
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 38 | |
| Podcasts | 22 | |
| YouTube | 9 |
The trial
ClinicalTrials.gov- Official title
- Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd Multi-arm Multi-stage Randomised Controlled Trial (STAMPEDE2).
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Stereotactic Ablative Body Radiotherapy (SABR); 177Lu-PSMA-617; Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI); Radiotherapy to Prostate ± Pelvic Nodes; Docetaxel
- Arms
- Arm A of SABR Comparison · Active comparator
- Arm S of SABR Comparison · Experimental
- Arm A of 177Lu-PSMA-617 Comparison · Active comparator
- Arm P of 177Lu-PSMA-617 Comparison · Experimental
- Enrollment
- 3,360 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- University College, London with Cancer Research UK, Novartis
- Start
- Jun 11, 2024
- Primary completion
- Apr 2031 (estimated)
- Results posted
- No
- Registry record
- NCT06320067 · updated Sep 26, 2025